These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 26488905)

  • 1. Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study.
    Clemow DB; Mason OW; Sarkis EH; Ruff DD; Berman BD; Donnelly CL; Robb AS; Holland DS; Schuh KJ; Barnes JM; Araujo AB
    Expert Rev Neurother; 2015; 15(11):1353-66. PubMed ID: 26488905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.
    Clemow DB; Nyhuis AW; Robinson RL
    CNS Neurosci Ther; 2016 Dec; 22(12):970-978. PubMed ID: 27476490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
    Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study.
    Surman C; Hammerness P; Petty C; Doyle R; Chu N; Gebhard N; Williams C; Biederman J
    CNS Neurosci Ther; 2010; 16(1):6-12. PubMed ID: 20070786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attention-deficit/hyperactivity disorder Under Treatment Outcomes Research (AUTOR): a European observational study in pediatric subjects.
    Haynes V; Lopez-Romero P; Anand E
    Atten Defic Hyperact Disord; 2015 Dec; 7(4):295-311. PubMed ID: 26115621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.
    Ercan ES; Akyol Ardic U; Kabukcu Basay B; Ercan E; Basay O
    Atten Defic Hyperact Disord; 2013 Dec; 5(4):377-85. PubMed ID: 23737214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
    McBurnett K; Clemow D; Williams D; Villodas M; Wietecha L; Barkley R
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):38-42. PubMed ID: 27845858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post Hoc Analysis of Potential Predictors of Response to Atomoxetine for the Treatment of Adults with Attention-Deficit/Hyperactivity Disorder using an Integrated Database.
    Bushe C; Sobanski E; Coghill D; Berggren L; De Bruyckere K; Leppämäki S
    CNS Drugs; 2016 Apr; 30(4):317-34. PubMed ID: 27055440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).
    Prasad S; Harpin V; Poole L; Zeitlin H; Jamdar S; Puvanendran K;
    Curr Med Res Opin; 2007 Feb; 23(2):379-94. PubMed ID: 17288692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI; Song DH; Shin DW; Kim JH; Lee YS; Hwang JW; Park TW; Yook KH; Lee JI; Bahn GH; Hirata Y; Goto T; Takita Y; Takahashi M; Lee S; Treuer T
    Asia Pac Psychiatry; 2014 Dec; 6(4):386-96. PubMed ID: 25345739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does stimulant pretreatment modify atomoxetine effects on core symptoms of ADHD in children assessed by quantitative measurement technology?
    Wehmeier PM; Dittmann RW; Banaschewski T; Schacht A
    J Atten Disord; 2014 Feb; 18(2):105-16. PubMed ID: 22617861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.
    Yang R; Gao W; Li R; Zhao Z
    Int J Neuropsychopharmacol; 2015 Apr; 18(8):. PubMed ID: 25896257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.